AbCellera partners with Vertex for T-cell engager autoimmune treatment

AbCellera collaborated with Vertex Pharmaceuticals to develop multispecific T-cell engagers, receiving $28.1 million in upfront payments. The deal strengthens AbCellera's position in the advanced autoimmune and immunology markets.